NEW YORK (TheStreet) -- Investors haven't been kind to MannKind (MNKD) - Get Report Tuesday following a downgrade from Goldman Sachs to sell from neutral. Analysts also slashed their price target for the stock to $3 from $6.

Shares recently fell nearly 9% to $6.10. 

The report was "unkind," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said during CNBC's "Stop Trading" segment. The downgrade came a day after the company's inhalable insulin treatment, Afrezza, got a lackluster review from an independent arbiter.

The "so negative" analyst report has created a "problematic situation," Cramer said. 


MannKind MNKD data by YCharts

Image placeholder title

-- Written by Bret Kenwell

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.